SALT LAKE CITY, Aug. 17, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Palmetto GBA, the Medicare contractor who oversees the MolDx program and Anthem, Inc., one of the largest private insurers in the country, have announced positive coverage decisions for EndoPredictÂ® testing. Â
RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules
- RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territoriesÂ Â Â Â Â Â Â Â Â
- Esomeprazole Strontium DR Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI), indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions
- RedHill expects to initiate the U.S. promotion of Esomeprazole Strontium DR Capsules 49.3 mg in the coming weeks
- Esomeprazole Strontium DR Capsules 49.3 mg will be the third commercial GI product to be promoted by RedHill in the U.S.
- RedHillâs GI-focused sales force currently promotes two GI specialty products in the U.S., DonnatalÂ® and EnteraGamÂ®, setting the stage for the potential launch of RedHillâs late clinical-stage GI products, if approved by the FDA
- PPIs are one of the most commonly prescribed class of medications in the U.S., with an estimated market value exceeding $20 billion in 2016
RAPS Publishes 10th Edition of Essential Text on US Regulatory Affairs, Plus Sector-Specific Books on Medical Devices and Biopharmaceuticals
Rockville, MD, USA, Aug. 16, 2017 (GLOBE NEWSWIRE) -- The Regulatory Affairs Professionals Society (RAPS) has published the updated, 10th edition of Fundamentals of US Regulatory Affairs, the most extensive reference available on regulatory affairs for pharmaceuticals, medical devices, biologics and other healthcare products intended for the US market. The book is an essential reference for anyone responsible for products that must comply with regulations from the US Food and Drug Administration (FDA) and other relevant US agencies.
Link Revised - Dr. Schwartz CEO of SKLN and Dr. Garvin with CytoBioscience Discuss Positive Results of a Merger in Progress with Their Two Companies
Eagan, MN , Aug. 16, 2017 (GLOBE NEWSWIRE) -- Link Revised - Dr. Schwartz CEO of SKLN and Dr. Garvin with CytoBioscience Discuss Positive Results of a Merger in Progress with Their Two Companies
Dr. Schwartz CEO of SKLN and Dr. Garvin with CytoBioscience Discuss Positive Results of a Merger in Progress with Their Two Companies
Eagan, MN , Aug. 16, 2017 (GLOBE NEWSWIRE) -- Dr. Schwartz CEO of SKLN and Dr. Garvin with CytoBioscience Discuss Positive Results of a Merger in Progress with Their Two Companies
Monsanto and ToolGen Announce Global Licensing Agreement on CRISPR Platform, Underscore the Benefits of Innovation for Farmers
ST. LOUIS and SEOUL, South Korea, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Monsanto Company (NYSE:MON) and ToolGen, Inc. (KONEX, 199800), a biotechnology company specializing in genome editing, announced today that the companies have reached a global licensing agreement for the use of ToolGenâs CRISPR technology platform to develop agricultural products.
Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2017 Financial Results
NEWTOWN, Pa., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today provided a corporate update and reported financial results for the second quarter ended June 30, 2017.
OncoCyte Confirms Launch Plans for Lung Cancer Diagnostic Test; Reports Progress Toward CLIA Lab Licensing and Second Quarter 2017 Financial Results
- Introduces Lung Cancer Diagnostic Branding-
COO Anthony Dudzinski was Interviewed on Uptick Network on Product Importance and Company Improvements
Eatontown, NJ , Aug. 14, 2017 (GLOBE NEWSWIRE) -- COO Anthony Dudzinski was Interviewed on Uptick Network on Product Importance and Company Improvements
VANCOUVER, British Columbia and WARMINSTER, Pa., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the company will present a corporate overview and business update at the 2017 Wedbush PacGrow Healthcare Conference at 10:55am ET on Wednesday, August 16, 2017, at Le Parker Meridien in New York.
CONSHOHOCKEN, Pa., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Symphony Health, a leading provider of data, cloud-based analytics and consulting solutions to life science companies and healthcare organizations, today announces the launch of a new series of high-deductible health plan (HDHP) analytics from the companyâs Managed Markets consulting practice.
Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be Included in the European Cystic Fibrosis Clinical Trial Network
HAYWARD, Calif., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that the RESULT Phase 3 clinical study of Sollpura for exocrine pancreatic insufficiency due to cystic fibrosis has been approved by the European Cystic Fibrosis Society Clinical Trial Network (ECFS CTN) Executive Committee. The aim of the ECFS CTN is to intensify clinical research in the area of cystic fibrosis and to bring new medicines to patients as quickly as possible.Â Enrollment in RESULT, in both the US and EU, is on schedule and inclusion of the study in the ECFS CTN may further expedite patient recruitment for the RESULT clinical study.Â Topline data are expected at the end of 2017 to early 2018, depending on the speed of patient enrollment.
NORCROSS, Ga., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the three months ended June 30, 2017. These results are included in the Companyâs Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov.
Crown Bioscience Announces Second Quarter Results, Appoints Dr. Yangzhou Wang as Sr. VP of Global Operations
SANTA CLARA, Calif., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, cardiovascular and metabolic disease research, today announces its results for the second quarter ending June 30, 2017.
BURLINGAME, Calif., Aug. 11, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will present at the 2017 Wedbush PacGrow Healthcare Conference in New York City, New York. The presentation is scheduled for Wednesday, August 16, at 1:20pm Eastern Time.
-Company Reports Revenue of $5.3 Million for Q2 2017-
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probodyâ¢ therapeutics for the treatment of cancer, will present at the 2017 Wedbush PacGrow Healthcare Conference.Â Debanjan Ray, chief financial officer and head of corporate development will deliver a corporate overview on August 16, 2017, at 2:30 p.m. ET.
RESEARCH TRIANGLE PARK, N.C., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Metabolon, Inc., the global leader in metabolomics, now offers more than 150 qualified and/or validated targeted biochemical assays for pharmaceutical and biotechnology R&D. These assays focus on specific metabolites or metabolic pathways and can be used to track biomarkers and enhance biological understanding across preclinical and clinical research. Developed biomarker assays reflect the evolution of global metabolomics and are excellent tools to rapidly and accurately establish pharmacodynamics and monitor efficacy and safety in clinical trials. The role of biomarkers is also expanding to inform new therapeutic indications and disease targets, patient segmentation and novel mechanisms of action. Interested parties can register here to participate in a free webinar highlighting the value of targeted biochemical assays on Tuesday, August 15, 2017, at 11am EDT.
- Completed patient enrollment in Phase 2 clinical study of MGL-3196, a liver-directed thyroid hormone receptor (THR) beta selective agonist, for treatment of NASH Â-